BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11953143)

  • 1. [An analysis of double autologous hemopoietic stem cell transplantation for hematological malignancies].
    Zhang B; Huang W; Da W; Zhang Z; Yao S; Gao C; Han X; Wu X; Wang Q; Yu L; Zhang M; Jin H
    Zhonghua Yi Xue Za Zhi; 2002 Jan; 82(2):123-6. PubMed ID: 11953143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical efficacy of double autologous hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia].
    Huang W; Zhang B; Yao S
    Zhonghua Xue Ye Xue Za Zhi; 2001 Aug; 22(8):399-402. PubMed ID: 11718088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined high dose chemotherapy with autologous stem cell transplantation and total body radiotherapy for 32 malignant lymphoma patients].
    Wang H; Cui X; Shao Y
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):436-8. PubMed ID: 11810783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hematopoietic stem cell transplantation for hematological malignancies].
    Zhong MZ; Chen FP; Shu YG
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):242-4. PubMed ID: 12575304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Total body irradiation etoposide followed by autologous hematopoietic stem cell transplantion for non-Hodgkin's lymphoma].
    Shi Y; Lei Y; Zhou S
    Zhonghua Yi Xue Za Zhi; 1998 Sep; 78(9):658-61. PubMed ID: 11038787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of malignant lymphoma by autologous hematopoietic stem cell transplantation combined with high dose radiotherapy and chemotherapy].
    Wang HQ; Cui XZ; Ren XB; Liu XM; Dai RZ; Zhang HL; Huang WY; Li W; Hao XS
    Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(11):948-51. PubMed ID: 12899794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
    Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
    Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous peripheral blood stem cell transplantation in the patients with hematologic malignancies and solid tumors.
    Ke X; Yang Y; Zhao X; Wang L
    Chin Med J (Engl); 2001 Feb; 114(2):196-9. PubMed ID: 11780206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
    Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
    J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
    Phillips GL; Meisenberg BR; Reece DE; Adams VR; Badros AZ; Brunner JL; Fenton RG; Filicko J; Grosso DL; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Mookerjee B; Nath R; Rapoport AP; Sarkodee-Adoo C; Takebe N; Vesole DH; Wagner JL; Flomenberg N
    Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complications of successively double autologous hemopoietic stem cell transplants].
    Huang WR; Da WM; Zhang BL; Gao CJ; Han XP; Jing Y; Wu XX; Zhao Y; Li HH; Wang QS; Zhang YZ; Bo J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):30-4. PubMed ID: 15748431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A clinical study of rhG-CSF in accelerating hematological recovery following autologous hematopoietic stem cells transplantation].
    Yang JL; Shi YK; He XH; Zhou SY; Zhou AP; Han XH; Liu P; Zhang CG; Ai B
    Ai Zheng; 2003 Aug; 22(8):785-9. PubMed ID: 12917020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantity and origin of transplanted autologous blood cells are independent factors associated with speed of postransplant hematological reconstitution.
    Rogulj D; Batinić D; Nemet D; Petrovecki M
    Croat Med J; 1999 Sep; 40(3):404-8. PubMed ID: 10411969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
    Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
    Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.
    Forrest DL; Nevill TJ; Naiman SC; Le A; Brockington DA; Barnett MJ; Lavoie JC; Nantel SH; Song KW; Shepherd JD; Sutherland HJ; Toze CL; Davis JH; Hogge DE
    Bone Marrow Transplant; 2003 Nov; 32(9):915-23. PubMed ID: 14561993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease.
    Gabarre J; Marcelin AG; Azar N; Choquet S; Lévy V; Lévy Y; Tubiana R; Charlotte F; Norol F; Calvez V; Spina M; Vernant JP; Autran B; Leblond V
    Haematologica; 2004 Sep; 89(9):1100-8. PubMed ID: 15377471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.